PEG-Intron
(Peginterferon alfa-2b)Phase 3Small molecule
Merck & Co.Peginterferon alfa-2b is used to treat chronic hepatitis C and melanoma by boosting the immune system to fight these diseases.[1] PEG-Intron is currently being investigated across 6 indications[3], with its most advanced program in Phase 3.[1]
PEG-Intron is one of 123 small molecule programs targeting Hepatitis B Virus Infection. It is currently in Phase 3.
6
Indications
77
Total Trials
4
Active Trials
122
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
71 competitors in Chronic Hepatitis
#DrugCompanyPhaseTrials
1Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Actos
TakedaApproved
PEG-Intron
Merck & Co.Phase 3
Glucophage
EMD SeronoApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Opdivo
Bristol-Myers SquibbPhase 2
Pegylated Interferon Alfa
Merck & Co.Phase 3
NA Therapy
GSKPhase 3
AHB-137
AAusper Biopharma Co., Ltd.
Phase 3
Hydronidone
BBeijing Continent Pharmaceutical Co, Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Hepatitis43 trials
Show 40 more trials
Hepatitis C15 trials
Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00018031·36 enrolled
Show 12 more trials
Fibrosis2 trials
Children1 trial
Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00006325·54 enrolled
15 more indications
HIV1 trial
Zidovudine Levels in HIV Infected Patients Being Treated for HCV
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00059358·16 enrolled
Metastatic Solid Tumors1 trial
Cirrhosis1 trial
Pediatric1 trial
TED1 trial
Osteosarcoma1 trial
Craniopharyngioma1 trial
Safety and Efficacy1 trial
Adjuvant1 trial
Malignant Melanoma1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Peginterferon alfa-2b. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Interferon Alpha/beta Receptor Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company